A refined 5-item subset of the Physical domain often used for FDA labelling due to its sensitivity to weight change.
Individuals with obesity undergoing clinical interventions. Focus: Weight-related quality of life.
A and a Total Score are also supported for comprehensive analysis. The scoring usually involves transforming raw scores into a scale from 0 to 100, where higher scores indicate better quality of life. How to Access the IWQOL-Lite-CT PDF
While clinical data focuses heavily on body mass index (BMI) or percentage of total body weight loss, the IWQOL-Lite-CT provides measurable quantitative data on how weight impacts a person's life across two core domains:
The IWQOL-Lite-CT was developed to provide a more focused and efficient tool compared to its predecessors. It consists of 20 items across several domains that are directly impacted by an individual's weight. This tool is particularly valuable in clinical trials for assessing the efficacy of weight loss interventions beyond just weight loss itself, focusing on how these interventions improve or affect patients' quality of life. iwqol-lite-ct pdf
Given the specificity of your query and without direct access to the PDF you're referring to, I'll provide a general deep write-up on the IWQOL-Lite-CT and its implications:
Standard discounts or waivers are frequently available for independent researchers, academic institutions, and student theses, but formal permission is still strictly required.
: This domain assesses how excess weight interferes with physical mobility, stamina, and basic daily activities. It includes questions regarding difficulty bending over, walking short distances, getting up from a chair, or managing physical discomfort.
The search for the typically arises from three specific needs: A refined 5-item subset of the Physical domain
"Is it... the pdf?" Thomas asked, his voice thin as tissue paper.
Yes. Official translations exist for Spanish (Latin American & European), German, French, and Japanese. You must request the "translated PDF" from the copyright holder; machine translations are not permitted for clinical trials.
Contact the tool’s authors directly. They are typically very responsive to academic and clinical requests. The licensing fee (if any) is modest for non-pharma academic research.
The IWQOL-Lite-CT has been deployed in numerous clinical trials for weight loss medications, including those for (the active ingredient in Wegovy and Ozempic) and tirzepatide (the active ingredient in Mounjaro and Zepbound), measuring improvements in physical function and psychosocial well-being alongside weight loss. Recent studies have used it to show that weight loss has a direct and significant positive effect on IWQOL-Lite-CT scores across the physical, psychosocial, and total score domains. A and a Total Score are also supported
The FDA’s Patient-Focused Drug Development (PFDD) guidelines emphasize that weight-loss medications must do more than just change numbers on a scale; they must improve how a patient feels and functions. The IWQOL-Lite-CT was specifically optimized to support product labeling claims for anti-obesity medications (AOMs). 2. Sensitivity to Clinical Change
The IWQOL-Lite-CT is a modified, optimized version of the classic IWQOL-Lite instrument. It was specifically redesigned and psychometrically validated to meet the stringent criteria set by regulatory bodies like the FDA for use in clinical trials.
The is a patient-reported outcome (PRO) measure designed to assess the impact of weight on physical and psychosocial functioning. It is an optimized version of the original IWQOL-Lite questionnaire, refined specifically for the context of clinical trials. Key Characteristics:
Developed in the 1990s as a comprehensive 74-item profile.
: Measuring the emotional impact of weight, including self-esteem, public distress, and social comfort.
We Can’t Wait To Help.